LS Investment Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 4.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,777 shares of the company’s stock after selling 3,708 shares during the quarter. LS Investment Advisors LLC’s holdings in Johnson & Johnson were worth $11,152,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. lifted its stake in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $124,000. Finally, Shine Investment Advisory Services Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $177,000. Hedge funds and other institutional investors own 65.70% of the company’s stock.
A number of equities research analysts have recently weighed in on the company. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research note on Monday, September 18th. Stifel Nicolaus upped their price target on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Citigroup upped their price target on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Jefferies Group raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $145.00 to $157.00 in a research report on Wednesday, October 11th. Finally, Argus upped their price target on Johnson & Johnson from $145.00 to $165.00 and gave the company a “positive” rating in a research report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $145.47.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the prior year, the company earned $1.68 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.